Research and Development Initiatives
A cascade of inflammatory events has shown to be correlative to a number of diseases. Imagenetix is focused on developing therapies which prevent inflammatory cell infiltration which can lead to a serious health condition.
Imagenetix’s first therapeutic drug is 1-TDC
Developed for the treatment and prevention of periodontal disease. Published studies conducted at Boston University have shown 1-TDC to halt the progression of gum and bone damage.